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Abstract 1 
Word Count:  216 2 
Background:  Prospective audit and feedback is a core antimicrobial stewardship program (ASP) 3 
strategy; however its impact is difficult to measure.   4 
Methods:  Our quasi-experimental study measured the effect of an ASP on clinical outcomes, 5 
antimicrobial use, resistance, costs, patient safety (adverse drug events [ADE] and Clostridium 6 
difficile infection [CDI]), and process metrics pre- (9/10–10/11) and post-ASP (9/12–10/13) using 7 
propensity adjusted and matched Cox proportional-hazards regression models and interrupted 8 
time series (ITS) methods. 9 
Results: Among our 2,696 patients, median length of stay was 1 day shorter post-ASP (5, 10 
interquartile range [IQR] 3-8 vs. 4, IQR 2-7 days, p<0.001).  Mortality was similar in both periods.  11 
Mean broad-spectrum (-11.3%), fluoroquinolone (-27.0%), and anti-pseudomonal (-15.6%) use 12 
decreased significantly (p<0.05).  ITS analyses demonstrated a significant increase in monthly 13 
carbapenem use post-ASP (trend: +1.5 days of therapy/1,000 patient days [1000PD] per month; 14 
95% CI 0.1-3.0).  Total antimicrobial costs decreased 14%.  Resistance rates did not change in 15 
the one-year post-ASP period.  Mean CDI rates/10,000PD were low pre- and post-ASP (14.2 ± 16 
10.4 vs. 13.8 ± 10.0, p=0.94).  Fewer patients experienced ADEs post-ASP (6.0% vs. 4.4%, 17 
p=0.06). 18 
Conclusions: Prospective audit and feedback has the potential to improve antimicrobial use and 19 
outcomes, and contain bacterial resistance.  Our program demonstrated a trend towards 20 
decreased length of stay, broad-spectrum antimicrobial use, antimicrobial costs, and adverse 21 
events.  22 
 3 
Word Count:  4,035 1 
Introduction 2 
Antimicrobial resistance is one of the greatest public health threats worldwide.[1]  In the United 3 
States (US), the Obama Administration recently identified antimicrobial resistance as a national 4 
security issue.[2]  Infections with antimicrobial-resistant bacteria and Clostridium difficile lead to 5 
increased morbidity, mortality, longer hospital stays, and dramatically increased healthcare 6 
costs.[3-5]  The Centers for Disease Control and Prevention estimated that in 2013, antimicrobial-7 
resistant organisms caused two million infections and 23,000 deaths in the US, with an additional 8 
14,000 deaths due to C. difficile infection (CDI).[1]  In the US, resistant infections are responsible 9 
for $20-35 billion in excess healthcare costs each year.[1]  10 
The driving forces that select for antimicrobial-resistant bacteria and promote CDI are 11 
antimicrobial use and suboptimal infection control practices.  While some cases of CDI are not 12 
associated with prior antibiotic use and many other risk factors for CDI exist, including advanced 13 
age and protein pump inhibitor use, antibiotic use remains the most important risk factor for the 14 
development of CDI.[6]  Given that over 50% of antimicrobial use in hospitals may be 15 
inappropriate, antimicrobial stewardship interventions (coordinated strategies to improve 16 
antimicrobial use) are critically important.[7]  The 2007 Infectious Diseases Society of America 17 
and Society for Healthcare Epidemiology of America guidelines for developing an antimicrobial 18 
stewardship program (ASP) have recognized prospective audit of antimicrobial use and feedback 19 
back to the prescriber and formulary restriction as two core strategies that provide the foundation 20 
of an ASP.[7]  Literature supports the effectiveness of prospective audit and feedback, however 21 
measuring the impact of these programs has been difficult.[8-17]  Therefore, the purpose of this 22 
study was to conduct a broad evaluation of a prospective audit and feedback ASP on the following 23 
six measures: 1) clinical outcomes, 2) antimicrobial utilization, 3) costs, 4) resistance, 5) patient 24 
safety (adverse drug events [ADE] and CDI), and 6) process metrics.  To our knowledge, our 25 
study is one of the first published studies to provide a comprehensive six-point assessment on 26 
 4 
the impact of an ASP.   1 
 2 
Methods 3 
We conducted a single-center quasi-experimental study.  Study metrics were compared pre-4 
(9/2010-10/2011) and post-ASP (9/2012-10/2013).  The study protocol was approved by the 5 
Institutional Review Board and the Research (IRB) and Development Committee of the 6 
Providence Veterans Affairs Medical Center (PVAMC).  The PVAMC IRB specifically waived the 7 
need for written informed consent for this retrospective study as it met the requirements of 38 8 
CFR 16.116(d). 9 
 10 
Intervention 11 
The PVAMC is a Veterans Affairs (VA) teaching hospital licensed for 119 beds.  In September 12 
2012, the PVAMC invested in and implemented a formal ASP.  Prior to formal introduction, the 13 
program was pilot tested for ~18 weeks between 10/2011-4/2012.  After that time the PVAMC 14 
funded a new ID fellowship position for pharmacists focusing in ASP.  The new ID pharmacist 15 
fellow began in July 2012 and spent the next two months writing the policy and getting it approved 16 
by hospital administration.  The ID pharmacist fellow began prospective audit and feedback in 17 
September 2012.  A second new ID pharmacist fellow joined the team in July 2013. The core 18 
members of the program included the co-directors (a board certified infectious diseases [ID] 19 
attending physician and a clinical pharmacist with formal ID fellowship training), two other board 20 
certified ID attending physicians, two ID pharmacist fellows, and when on rotation, ID physician 21 
fellows (~6 months), PGY-1 pharmacy practice residents and APPE students (~9 months).  22 
Infection control practitioners, microbiology laboratory personnel, and an epidemiologist 23 
supported the core team.  The main strategy implemented by the ASP was prospective audit and 24 
feedback.  Since formal introduction, core team members have provided prospective audit and 25 
feedback for every patient admitted with active antimicrobial orders (Monday-Friday). 26 
 5 
The on-service ID pharmacist fellow manually reviewed a list of all active antimicrobial 1 
orders daily.  The list was generated in the morning and all active orders were reviewed with no 2 
restrictions for how long the patient was on the antibiotic before review.  Each antimicrobial order 3 
was reviewed for appropriateness.  Appropriateness was determined by the ID pharmacist fellow, 4 
who reviewed each order to make sure the correct drug, dose, duration, and/or route were used.  5 
The ID pharmacist fellow also ensured there was an indication for the antimicrobial order.  No 6 
single definition for appropriateness was instituted, however the ID pharmacist fellow utilized 7 
institutional guidelines (PVAMC Antimicrobial Treatment Guidebook)  professional society 8 
guidelines, expert opinion of the ASP core members (pre-rounding with an ID physician and/or 9 
the senior clinical pharmacist), and local and regional resistance patterns to determine 10 
appropriateness.[7]   11 
The PVAMC has published an annually updated Antimicrobial Treatment Guidebook since 12 
2004, which contains empiric treatment guidelines, dosing recommendations, infection control 13 
policies, and an antibiogram of antimicrobial resistance rates.  Additionally, a pre-designed 14 
decision-support template was used to collect and organize pertinent clinical data for ASP 15 
interventions (Fig. 1).  Other antimicrobial stewardship principles such as intravenous (IV) to oral 16 
(PO) conversion, de-escalation of empiric therapy based on culture results, and antimicrobial 17 
optimization were used to make recommendations to improve “appropriateness”.[7]  Antimicrobial 18 
optimization involved recommendations to improve the drug, dose, or duration of the antimicrobial 19 
based on patient characteristics, causative organism, site/type of infection, and 20 
pharmacokinetic/pharmacodynamics characteristics.  Potential interventions were then relayed to 21 
the on-service ID physician and/or the senior clinical pharmacist.  These “ASP rounds” were 22 
conducted daily and generally ranged from 15-60 minutes. 23 
After discussing patients and interventions, verbal communication (telephone and in-24 
person) and/or written notes in the electronic medical record (EMR) were used to relay 25 
interventions to the provider.  The mode of communication (verbal or written by physician, 26 
 6 
pharmacist, or pharmacy resident/student) depended on the type of intervention that was needed.  1 
The specific intervention also dictated who made the intervention (physician, pharmacist, or 2 
pharmacy resident/student).  For example, for a simple IV to PO antimicrobial conversion (e.g. IV 3 
to PO ciprofloxacin), a pharmacy student or resident may have written a draft note.  However, 4 
discontinuation of an antimicrobial in a complex patient may have necessitated a phone call to 5 
the primary team by the on-service ID physician.  To alert the provider (usually the medical 6 
resident) of the note, they were added as co-signers.  The ID pharmacy fellow fully reviewed and 7 
signed-off on all notes written by residents and students before they were incorporated into the 8 
EMR.  Additionally, the ID pharmacy fellow alerted the on-service ID physician to all written notes 9 
for review and co-signature.  10 
 11 
Process Metrics 12 
During the post-study period, the on-service ID pharmacy fellow documented all patients that 13 
were reviewed by the ASP in an excel database.  Variables collected included admission date, 14 
treating specialty, antimicrobial indication, time-spent, and whether an intervention was made.  If 15 
an intervention was made, the pharmacy fellow documented the type of intervention made, the 16 
stewardship team member who made the intervention, intervention acceptance or non-17 
acceptance, and reasons for non-acceptance.  Acceptance or non-acceptance was qualified as 18 
a dichotomous variable for each recommendation made. Interventions were categorized as 19 
follows: vancomycin dosing or therapeutic drug monitoring, antimicrobial discontinuation, IV to 20 
PO conversion, de-escalation, antimicrobial optimization (i.e. change to optimize the antimicrobial 21 
drug, dose, or duration), antimicrobial discontinuation, or other. 22 
 23 
Clinical Outcomes 24 
Clinical outcomes were compared between patients pre- and post-ASP.  We identified all hospital 25 
inpatients with antimicrobials administered during the pre- and post-ASP periods.[18]  Patients 26 
 7 
with a long-term stay (> 90 days) were excluded.  Inpatient antimicrobial administrations were 1 
captured using patient barcode medication administration (BCMA) data. 2 
Outcomes included time to hospital discharge (length of stay [LOS]), 7-, 14-, and 30-day 3 
all-cause mortality, inpatient all-cause mortality, and 30-day readmission.  The index date for 4 
hospital discharge, 7-, 14- and 30-day mortality, and inpatient mortality was the date of 5 
antimicrobial initiation and for 30-day readmission was the date of hospital discharge.  We 6 
calculated the time from the index date to the date of event for each outcome.  Patients were 7 
censored on their date of death. 8 
We determined demographics, comorbid conditions, and health-care exposures from the 9 
national VA standardized databases which contain ICD-9 diagnostic and procedure codes, vital 10 
status, microbiology results, barcode medication administration, and laboratory results. 11 
 12 
Antimicrobial Utilization 13 
Antimicrobial utilization was compared pre- and post-ASP.  The antimicrobial utilization metric 14 
used was days of therapy per 1,000 patient days (DOT/1000PD) based on inpatient medication 15 
administration data.[19, 20]  We assessed overall antimicrobial use, as well as specific categories 16 
of use by route, agent, class, and spectrum.[21] 17 
 18 
Antimicrobial Costs 19 
Antimicrobial costs were estimated using the Average Wholesale Price. The cost metric used was 20 
cost per 1,000 patient-days.  Overall costs and costs for specific antimicrobial categories 21 
described above were compared pre- and post-ASP. 22 
 23 
Antimicrobial Resistance 24 
Antimicrobial resistance was assessed using PVAMC culture and susceptibility data 25 
(antibiogram).  Antimicrobial resistance for several important organism-antimicrobial 26 
 8 
combinations tested at the PVAMC were compared pre- and post-ASP.[1]  The organisms 1 
assessed included Enterococcus faecalis, Enterococcus faecium, methicillin-susceptible 2 
Staphylococcus aureus (MSSA), MRSA, Klebsiella pneumoniae, Acinetobacter baumannii, 3 
Pseudomonas aeruginosa, and Escherichia coli. 4 
 5 
Patient Safety 6 
Monthly episodes of CDI per 10,000 patient-days were compared pre- and post-ASP.  CDI 7 
episodes were obtained from VA Inpatient Evaluation Center (IPEC) data.[22, 23]  Rates of ADEs 8 
among hospital inpatients with antimicrobial administrations were compared pre- and post-ASP.  9 
ADEs were identified using ICD-9 codes for adverse effects of drugs. 10 
  11 
Statistical Analysis 12 
All analyses were performed using SAS (SAS Institute Inc., Cary, NC, Version 9.2). 13 
 14 
Process Metrics 15 
We used descriptive statistics, including means and percentages, to summarize the data.   16 
 17 
Clinical outcomes 18 
Baseline differences between patients in the pre- and post-ASP periods were assessed using 19 
Fisher’s exact or χ2 tests (categorical data), and a t-test or Wilcoxon Rank Sum test (continuous 20 
data), as appropriate.  Propensity score adjustment and matching was implemented to balance 21 
differences between patients in the pre and post-ASP periods.[24, 25]  Propensity scores were 22 
developed from an unconditional logistic regression model (manual backward elimination).  23 
Hazards ratios comparing clinical outcomes in post-ASP patients to pre-ASP patients were 24 
calculated from Cox proportional-hazards regression models. 25 
 26 
 9 
Antimicrobial utilization 1 
T-tests were used to compare mean DOT/1000PD pre- and post-ASP.  We utilized interrupted 2 
time series (ITS) methods to assess the impact of ASP on monthly antimicrobial utilization.  3 
Segmented linear regression models were used because they can tolerate fewer time points than 4 
autoregressive integrated moving average models.[26, 27]  We tested for autocorrelation using 5 
the Durbin-Watson statistic, and for seasonality/stationarity using the Dickey-Fuller unit root 6 
test.[27, 28]  Estimates for regression coefficients corresponding to the effect sizes of a change 7 
in level and a change in trend for post- to pre-ASP were obtained.  A change in level was defined 8 
as the difference between the observed level immediately post-ASP and the predicted level by 9 
the pre-ASP trend.  A change in trend was defined as the difference between the pre and post-10 
ASP slopes.   11 
 12 
Antimicrobial Costs 13 
T-tests were used to compare mean costs/1000PD pre- and post-ASP.  Segmented linear 14 
regression models were utilized to model temporal trends in monthly antimicrobial costs. 15 
 16 
Antimicrobial Resistance 17 
We used Fisher’s exact or χ2 tests, as appropriate, to compare the number of resistant and 18 
susceptible isolates for select organism-antimicrobial combinations pre- and post-ASP. 19 
 20 
Patient Safety 21 
A t-test was used to compare mean CDI rate/10,000PD and the χ2 test was used to compare 22 
ADEs pre- and post-ASP.  Segmented linear regression models were utilized to model temporal 23 
trends in monthly CDI rates. 24 
 25 
Results 26 
 10 
Process Metrics 1 
During the post-ASP period, we reviewed 1,049 patient charts. Interventions were made in 36.7% 2 
of patients reviewed.  The most common interventions made were antimicrobial optimizations, IV 3 
to PO conversions, and discontinuations (Fig. 2).  Among the patients with an intervention, 4 
interventions were most often (88.3%) made through a written note in the patients’ EMR.  The on-5 
service pharmacy fellow made the intervention in almost half of the patients who needed an 6 
intervention (47.8%).  Overall, 522 interventions were made with an overall acceptance rate of 7 
77.2%.  The most common reasons for non-acceptance, were that the primary team never viewed 8 
the recommendation (29%) or that the antimicrobial was changed/discontinued (14%) and 9 
therefore the recommendation was no longer applicable.  10 
 11 
Clinical Outcomes 12 
We identified 2,696 patients treated with antimicrobials in the pre- (49.0%, n=1,321) and post-13 
ASP (51.0%, n=1,375) periods.  The median patient age was ~70 years in both groups (Table 1).  14 
The median Charlson (2 vs. 4) and Elixhauser (3 vs. 5) scores were higher for patients post-ASP 15 
(p<0.001).  History, in the year prior to the antibiotic-related admission, of diabetes, congestive 16 
heart failure, myocardial infarction, chronic respiratory disease, and chronic renal disease were 17 
more common among post-ASP patients.  Diagnoses of cellulitis, osteomyelitis, and influenza 18 
during the current admission were more common for patients post-ASP (Table 1).  More post-19 
ASP patients were hospitalized in the 90 days prior to admission than pre-ASP (Table 2).  Despite 20 
these differences between pre- and post-ASP patients, we were able to balance significantly 21 
different baseline characteristics using propensity scores. 22 
The median LOS was 1 day shorter post-ASP (5 days, IQR 3-8 vs. 4, IQR 2-7; p<0.001).  23 
In unadjusted analysis, time to discharge (LOS) was significantly shorter post-ASP (Table 3; HR 24 
1.18, 95% CI 1.09-1.27).  Unadjusted 30-day readmission was significantly higher post-ASP (HR 25 
1.24, 95% CI 1.08-1.42).  However, there was no difference in the propensity adjusted and 26 
 11 
matched analyses (553 matched pairs) for time to discharge or 30-day readmission.  While all-1 
cause 7- and 14- day mortality were similar between the two periods in all analyses, 30-day 2 
mortality was greater post-ASP in propensity adjusted analyses (HR 1.41, 95% CI 1.01-1.96); 3 
however a difference was not observed in unadjusted or propensity matched analyses. 4 
 5 
Antimicrobial Utilization 6 
There was no difference in the overall mean DOT/1000PD between the pre- and post-ASP 7 
periods (Table 4).  However, there was a significant (p<0.05) decrease in mean broad-spectrum 8 
use (-11.3%), specifically driven by fluoroquinolones (-27.0%) and anti-pseudomonals (-15.6%).  9 
IV use decreased (-4.6%, p=0.43) and digestive use increased (+8.3%, p=0.26).  All other 10 
antimicrobial categories assessed decreased non-significantly, except vancomycin (Fig 3.). 11 
 ITS analyses demonstrated several significant level changes for antimicrobial use, 12 
including digestive, anti-CDI, and anti-anaerobic use (Table 5).  The only significant change in 13 
month-to-month trend observed was with carbapenems (+1.5 DOT/1000PD per month; 95% CI 14 
0.1-3.0, p=0.035). 15 
 16 
Antimicrobial Costs 17 
Total antimicrobial costs decreased 14% pre- to post-ASP, with a non-significant 5.3% decrease 18 
in mean antimicrobial costs/1000PD (p=0.5). The cost for fluoroquinolones decreased 29% pre- 19 
to post-ASP (p<0.05).  IV (-4.2%), digestive (-7.6%), and broad-spectrum (-9.5%) costs all 20 
decreased non-significantly.   21 
 ITS demonstrated several significant increases in antimicrobial costs immediately 22 
following the implementation of ASP.  While the level of anti-CDI, anti-anaerobic, and broad-23 
spectrum costs increased, this increase was not sustained during the post-ASP period. 24 
 25 
Antimicrobial Resistance 26 
 12 
No significant changes in antimicrobial resistance were observed for any of the Gram-positive or 1 
Gram-negative organism-antimicrobial combinations assessed (Table 6), except for Klebsiella 2 
pneumoniae, in which several significant (p<0.05) increases in resistance were observed.   3 
 4 
Patient Safety 5 
The mean rate of CDI/10,000PD was 14.2 ± 10.4 pre-ASP and 13.8 ± 10.0 post-ASP (p=0.94).  6 
No significant changes in level or trend of CDI/10,000PD per month were observed.  Fewer 7 
patients experienced ADEs post-ASP (6.0% vs. 4.4%, p=0.06). 8 
 9 
Discussion 10 
Currently, there is no consensus on which metrics are the most optimal to adequately assess the 11 
impact of an ASP.[29]  Our study provides a detailed assessment of the impact of an ASP on 12 
clinical outcomes, antimicrobial utilization, costs, resistance, patient safety, and process metrics. 13 
Due to the challenges associated with outcomes assessment, most studies to date have focused 14 
on measuring the impact of an ASP on just one or two metrics, most commonly antimicrobial 15 
utilization and costs. 16 
While median LOS was 1 day shorter post-ASP, this difference was not statistically 17 
significant in propensity matched or adjusted analyses.  Despite patients being generally sicker 18 
post-ASP (higher Charlson and Elixhauser scores and higher prevalence of several 19 
comorbidities), ASP interventions may have led to improved quality of care, enabling patients to 20 
be discharged sooner.  Nonetheless, in general, ASP implementation had a limited impact on the 21 
clinical outcomes assessed.  These findings are similar to most studies, which have demonstrated 22 
little to no impact of prospective audit and feedback ASPs on clinical outcomes, including LOS,[8-23 
17] mortality,[8-10, 12-17] and 30-day readmission.[10, 14]  This may be because, a large number 24 
of factors affect clinical response and outcomes, and therefore the independent effect of ASP 25 
interventions on these outcomes may be negligible.[29]  Additionally, while in adjusted analyses 26 
 13 
30-day mortality was higher post-ASP, this included deaths due to all-causes.  The Centers for 1 
Medicare and Medicaid Services (CMS) 30-day risk standardized mortality rates for congestive 2 
heart failure at the Providence VA Medical Center were higher during the post-ASP period than 3 
the pre-ASP period.[30]  .Also, antimicrobial stewardship interventions are likely to have a greater 4 
impact on 7- and 14-day mortality and inpatient mortality, which did not differ between periods.   5 
We also measured the effect of our ASP on antimicrobial resistance. In another study, 6 
reduction of broad-spectrum antimicrobial use was not associated with improvements in the 7 
hospital antibiogram.[31]  As with clinical outcomes, the factors associated with antimicrobial 8 
resistance are complex and involve many factors such as infection control, antimicrobial use 9 
within and outside the hospital, and patient colonization and immune status.  Therefore, it can be 10 
challenging for an ASP to demonstrate a favorable impact on antimicrobial resistance.[32]  11 
Moreover, it can take years before a program has an effect on antimicrobial resistance.  12 
In our assessment of antimicrobial use, we did not observe a decrease in overall mean 13 
antimicrobial use, which may be related to the appropriateness of antimicrobial utilization prior to 14 
implementation of our ASP.  It is estimated that 50% of antimicrobial use in hospitals is 15 
inappropriate.[7]  However, in our study, only 37% of patient records reviewed were deemed to 16 
require intervention.  Since 2004, a clinical pharmacist with formal training in infectious diseases 17 
has provided the PVAMC expert consultation, an antimicrobial guide with empiric treatment 18 
recommendations and an antibiogram, and educational programs.  Additionally, several broad-19 
spectrum antimicrobials have been restricted since before the implementation of our ASP.  20 
Therefore, at baseline appropriate antimicrobial use at the PVAMC may have been relatively high. 21 
Though overall use did not decrease, we did see significant reductions in broad-spectrum, 22 
fluoroquinolone, and anti-pseudomonal use post-ASP.  Our ASP improved the use of these broad-23 
spectrum antimicrobials, through appropriate antimicrobial de-escalation and optimization.  We 24 
also observed a reduction in mean carbapenem use post-ASP, however ITS demonstrated an 25 
 14 
increasing trend in carbapenem use.  This highlights the importance of conducting ITS analysis 1 
to uncover immediate and sustained changes in outcome measures over time.  This increasing 2 
trend in carbapenem use may be due in part to rotating medical residents.  At the PVAMC, 3 
residents are the primary antimicrobial prescribers, and they rotate out of the PVAMC to other 4 
local hospitals every month.  At the time of this study, the PVAMC had the only comprehensive 5 
multidisciplinary ASP in the area.  Moreover, there was no formal ASP at the flagship hospital that 6 
the residents rotate through.  Therefore residents may have not been used to the ASP service.  7 
In a recent study, investigators demonstrated an improvement in the level of audited 8 
antimicrobials but no change in the trend, which was also likely due to residents changing to 9 
different departments or institutions frequently.[15]  Monthly introductions of the house-staff and 10 
new medical residents to our ASP and other educational material such as newsletters or posters, 11 
may increase residents’ awareness and connection to our service, and improve the ASP culture 12 
at the PVAMC.  The increasing trend in carbapenem use may also be related, in part, to the 13 
significant increases in resistance observed for Klebsiella pneumoniae.  14 
 Measuring the impact of ASPs on patient safety is also important.  Rates of CDI were 15 
similar pre- and post- ASP.  This is not surprising, as CDI rates were already low prior to ASP 16 
implementation, likely due to strong infection control practices.  Infection control has had 17 
guidelines for the prevention and control of CDI since before the pre-ASP period.  Guidelines 18 
include barrier methods, contact precautions, hand hygiene, and environmental infection control 19 
methods.  Additionally, we observed a trend towards decreased ADEs post-ASP.  Due to the 20 
difficulties in obtaining accurate data, very few studies have assessed the impact of ASPs on 21 
ADEs.[33] 22 
 Our ASP did not have a significant impact on the clinical outcome measures assessed.  23 
This may be due in part to the outcomes metrics chosen.  As previously mentioned, the most 24 
optimal metrics to demonstrate the value of an ASP are largely unknown.[29]  As we continue to 25 
 15 
strengthen our program, we look to assess additional metrics such as infection-related clinical 1 
outcomes and total costs of care, not just drug costs, and to assess the impact of these outcomes 2 
over a longer follow-up period.  Additionally, almost 90% of our recommendations were made 3 
through written notes.  Our feedback may have had a greater impact if it was provided through 4 
face-to-face communication or phone calls directly to the provider.  Notes left in the chart are 5 
unlikely to be seen in a timely manner.[34]  Busy providers may miss or ignore notes.  Moreover, 6 
the impact of our program may be limited by the timeliness of final culture results.  At the PVAMC, 7 
traditional microbiologic testing (culture and susceptibility) is primarily utilized, which is suboptimal 8 
in providing rapid organism identification and susceptibility results.[35]  Previous research by our 9 
group has demonstrated that the median time to final culture results ranged from 3-5 days at our 10 
facility and regionally.  Therefore, incorporation of rapid diagnostic testing (RDT) could 11 
significantly enhance the impact of our ASP.[35]  RDT has the potential to improve clinical 12 
outcomes, costs, and resistance rates by decreasing the time to appropriate therapy and quickly 13 
stopping unnecessary therapy. 14 
There are several limitations to our study.  The quasi-experimental design is associated 15 
with a number of inherent limitations, including the potential for confounding bias.  However, we 16 
did our best to control for differences between patients in the pre- and post-ASP periods through 17 
propensity score adjustment and matching.  Still, differences in unmeasured factors may exist 18 
between the groups.  We may not have been able to capture all residual confounding, and having 19 
a generally sicker population in the post-period may bias estimates of differences in clinical 20 
outcomes towards the null.  Of note, while there were no outbreaks at the PVAMC in either period, 21 
the 2012-2013 influenza season started earlier in Rhode Island and was more severe than 22 
previous years (including the 2010-2011 season).[36, 37]  Significantly more patients in the post-23 
ASP period had a diagnosis of influenza than in the pre-ASP period.   24 
As with any study that utilizes secondary data sources, this study may be limited by the 25 
accuracy of the data contained within the various data sources.  While we attempted to develop 26 
 16 
accurate definitions for outcomes and potential confounders, misclassification bias may still affect 1 
our results.  However, the VA has used an electronic medical record for over 15 years, from which 2 
the VA research databases are extracted, and the accuracy and completeness of several VA 3 
datasets has been verified in previous studies.[38-41] 4 
It is unclear how long it takes for changes in antimicrobial utilization to subsequently impact 5 
resistance rates and clinical outcomes.  Our study only assessed the first year post-6 
implementation.  Therefore, it is possible that we did not allow enough time to observe an effect, 7 
as it may take several years of follow-up.  However, we utilized interrupted time series analysis 8 
which is the strongest approach to quantify the effects of an intervention over time for quasi-9 
experimental studies.[27]  Additionally, since few deaths occurred, we may not have been able to 10 
detect a difference between groups.  Finally, we conducted a single center VA study and the 11 
generalizability of our study may be limited to the VA setting.  VA patients tend to differ from the 12 
general population in terms of patient demographics and comorbidities, and the VA has unique 13 
resources, which may assist with ASP efforts.  Nonetheless, our study could serve as an example 14 
to other burgeoning stewardship programs that are interested in analyzing the potential 15 
effectiveness of their interventions. 16 
 17 
Conclusions 18 
Our prospective audit and feedback program was associated with improvements in broad-19 
spectrum antimicrobial use.  While median LOS was shorter post-ASP, clinical outcomes were 20 
similar pre- and post-ASP.  Resistance, costs and patient safety indicators did not significantly 21 
change, but these changes may have a positive impact long term.  Further measures, such as 22 
increased use of RDT, increased direct verbal feedback, and additional outcomes metrics, may 23 
be necessary moving forward.  Moreover, as our ASP has now been in effect for over three years, 24 
we look to continue to measure the sustained impact of our program over time. 25 
Overall, prospective audit and feedback has the potential to improve antimicrobial use and 26 
 17 
outcomes, and contain bacterial resistance.  Our program demonstrated a trend towards 1 
decreased length of stay, broad-spectrum antimicrobial use, antimicrobial costs, and adverse 2 
drug events.  While these results were not statistically significant, we believe that these findings 3 
have important clinical impact to the care of our patients.   4 
 5 
 6 
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Table 1. Demographics and Comorbid Conditions by Period. 1 
Demographic characteristics 
Pre-Antimicrobial 
Stewardship Period 
(n=1,321) 
Post-Antimicrobial 
Stewardship Period 
(n=1,375) 
Age (years) 71.0 (62.0-82.0) 70.0 (62.0-82.0) 
Male Gender 1,289 (97.6) 1,324 (96.3) 
White Race 1,208 (91.4) 1,280 (93.1) 
Ethnicity 
Non-Hispanic 
Hispanic 
Unknown 
  
1,293 (97.9) 1,338 (97.3) 
7 (0.5) 19 (1.4) 
21 (1.6) 18 (1.3) 
Marital Status* 
     Married 
     Divorced / Separated 
     Widowed 
     Single/ Never Married 
     Unknown 
 
484 (36.6) 
 
497 (36.1) 
401 (30.4) 454 (33.0) 
224 (17.0) 261 (19.0) 
206 (15.6) 154 (11.2) 
6 (0.5) 9 (0.7) 
Body Mass Index* 
<18.5 
18.5-24.9 
25.0-29.9 
30+ 
Unknown 
 
35 (2.6) 
 
15 (1.1) 
560 (42.4) 622 (45.2) 
257 (19.5) 246 (17.9) 
435 (32.9) 475 (34.5) 
34 (2.6) 17 (1.2) 
Charlson Score* 2.0 (1.0-4.0) 4.0 (2.0-6.0) 
Elixhauser Score* 3.0 (1.0-5.0) 5.0 (3.0-7.0) 
Medical History within One Year Prior 
to the Antibiotic-Related Admission 
    
Alcohol Abuse* 216 (16.4) 295 (21.5) 
Amputation* 46 (3.5) 78 (5.7) 
Any Cancer 310 (23.5) 361 (26.3) 
Burns* < 5 12 (0.9) 
Cardiac Arrhythmia* 386 (29.2) 461 (33.5) 
Chronic Renal Disease* 240 (18.2) 274 (19.9) 
Chronic Respiratory Disease* 528 (40.0) 662 (48.1) 
Chronic Ulcer* 145 (11.0) 232 (16.9) 
Complication of Implant or Graft 71 (5.4) 89 (6.5) 
Congestive Heart Failure 303 (22.9) 346 (25.2) 
Coronary Heart Disease* 430 (32.6) 497 (36.1) 
Depression* 460 (34.8) 657 (47.8) 
Diabetes* 461 (34.9) 539 (39.2) 
Drug Abuse* 133 (10.1) 168 (12.2) 
Fluid and Electrolyte Disorders* 357 (27.0) 551 (40.1) 
Gangrene* 16 (1.2) 41 (3.0) 
Hypertension* 774 (58.6) 982 (71.4) 
Hypothyroidism* 83 (6.3) 125 (9.1) 
Immunity Disorder < 5 < 5 
Metastatic Cancer 51 (3.9) 49 (3.6) 
Mild Liver Disease* 85 (6.4) 144 (10.5) 
Moderate/Severe Liver Disease* 25 (1.9) 47 (3.4) 
 23 
Myocardial Infarction* 107 (8.1) 150 (10.9) 
Neutropenia 12 (0.9) 14 (1.0) 
Paraplegia and Hemiplegia 44 (3.3) 71 (5.2) 
Peptic Ulcer Disease* 34 (2.6) 68 (4.9) 
Peripheral Vascular disease* 181 (13.7) 264 (19.2) 
Psychoses* 106 (8.0) 172 (12.5) 
Pulmonary Circulation Disorders* 57 (4.3) 104 (7.6) 
Rheumatoid Arthritis 26 (2.0) 27 (2.0) 
Surgery/Medical Complication* 68 (5.1) 183 (13.3) 
Tobacco Abuse* 251 (19.0) 371 (27.0) 
Infection Diagnosis (ICD-9) During 
Antibiotic-Related Admissiona 
  
Bacteremia 49 (3.7) 49 (3.6) 
Cellulitis or Abscess* 157 (11.9) 199 (14.5) 
Endocarditis < 5 6 (0.4) 
Influenza* < 5 49 (3.6) 
Osteomyelitis* 21 (1.6) 41 (3.0) 
Pneumonia 284 (21.5) 304 (22.1) 
Skin/Subcutaneous Infection 265 (20.1) 318 (23.1) 
Urinary Tract Infections 325 (24.6) 326 (23.7) 
Culture/Laboratory Confirmed 
Infections During Antibiotic-Related 
Admission 
  
Bacteremiab 59 (4.5) 46 (3.3) 
Clostridium difficile Infectionc 73 (5.5) 85 (6.2) 
Influenzac* < 5 32 (2.3) 
Pneumoniac 45 (3.4) 49 (3.6) 
Skin/Subcutaneous Tissue  
Infectionc 
50 (3.8) 72 (5.2) 
Urinary Tract Infectionc 170 (12.9) 168 (12.2) 
Positive Culture During Antibiotic-
Related Admissiond 
  
Enterococcus faecalis 24 (1.8) 30 (2.2) 
VRE* 8 (0.6) < 5 
MSSA 42 (3.2) 39 (2.8) 
MRSA 42 (3.2) 45 (3.3) 
Streptococcus species* 5 (0.4) 30 (2.2) 
Escherichia coli 61 (4.6) 48 (3.5) 
Klebsiella pneumoniae 47 (3.6) 37 (2.7) 
Pseudomonas aeruginosa 55 (4.2) 38 (2.8) 
Fungal species* < 5 50 (3.6) 
Previous Infection Diagnosis (ICD-9) 
within One Year Prior to the 
Antibiotic-Related Admissiona 
  
Bacteremia 41 (3.1) 59 (4.3) 
Cellulitis or Abscess* 168 (12.7) 282 (20.5) 
Gram-negative* 37 (2.8) 70 (5.1) 
Influenza* 5 (0.4) 32 (2.3) 
Osteomyelitis* 24 (1.8) 77 (5.6) 
Pneumonia* 197 (14.9) 327 (23.8) 
 24 
Pseudomonas* 17 (1.3) 52 (3.8) 
Skin/ Subcutaneous Tissue 
Infections* 
264 (20.0) 416 (30.3) 
Staphylococcus aureus* 19 (1.4) 45 (3.3) 
MRSA 39 (3.0) 59 (4.3) 
Streptococcus species* 27 (2.0) 63 (4.6) 
Surgical Site Infection* 11 (0.8) 48 (3.5) 
Urinary Tract Infections* 238 (18.0) 362 (26.3) 
Previous Culture/Laboratory 
Confirmed Infections within One Year 
Prior to the Antibiotic-Related 
Admission 
  
Bacteremiab 74 (5.6) 66 (4.8) 
Bone and Joint*c 14 (1.1) 33 (2.4) 
Clostridium difficile Infectionc 77 (5.8) 96 (7.0) 
Influenza*c < 5 15 (1.1) 
Pneumonia*c 33 (2.5) 61 (4.4) 
Skin/Subcutaneous Tissue 
Infection*c 
65 (4.9) 126 (9.2) 
Urinary Tract Infections*c 178 (13.5) 286 (20.8) 
Previous  Positive Culture within One 
Year Prior to the Antibiotic-Related 
Admissiond 
  
Enterococcus faecalis*  37 (2.8) 75 (5.5) 
VRE* 16 (1.2) < 5 
MSSA 72 (5.5) 75 (5.5) 
MRSA 86 (6.5) 80 (5.8) 
Streptococcus species* < 5 33 (2.4) 
Escherichia coli 88 (6.7) 110 (8.0) 
Klebsiella pneumoniae 95 (7.2) 95 (6.9) 
Pseudomonas aeruginosa 73 (5.5) 81 (5.9) 
Fungal species* < 5 48 (3.5) 
Data are mean ± standard deviation, median (interquartile range), or number (%) of patients.  1 
Differences assessed by Fisher’s exact or χ2 test (categorical data), t-test or Wilcoxon Rank Sum 2 
test (continuous data) as appropriate.  3 
 4 
MSSA=methicillin-sensitive Staphylococcus aureus; MRSA=methicillin-resistant Staphylococcus 5 
aureus; VRE=vancomycin-resistant Enterococcus. 6 
 7 
*= p<0.05 8 
a= Infection defined by presence of ICD-9 code. 9 
b= Bacteremia defined by positive blood culture from any organism excluding coagulase-negative 10 
Staphylococcus species. 11 
c= Infection defined by presence of ICD-9 code and positive corresponding culture. 12 
d= Positive culture from any site. 13 
 14 
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Table 2. Healthcare and Antibiotic Exposures and Hospitalization-Related Characteristics 1 
by Period. 2 
 3 
Healthcare and Antibiotic Exposures and 
Hospitalization-Related Characteristics 
Pre-Antimicrobial 
Stewardship 
Period (n=1,321) 
Post-Antimicrobial 
Stewardship Period 
(n=1,375) 
Treatment specialty 
Intensive Care Unit 
General Medicine 
Surgery  
Other 
124 (9.4) 116 (8.4) 
1013 (76.7) 1084 (78.8) 
140 (10.6) 125 (9.1) 
44 (3.3) 50 (3.6) 
Antibiotic Exposures during the current 
Admission  
  
Piperacillin/Tazobactam 379 (28.7) 353 (25.7) 
Vancomycin 383 (29.0) 393 (28.6) 
3rd/ 4th Generation Cephalosporins 274 (20.7) 286 (20.8) 
Beta-lactam/ Beta-Lactamase Inhibitors 411 (31.1) 401 (29.2) 
Fluoroquinolones* 537 (40.7) 452 (32.9) 
Carbapenems 41 (3.1) 28 (2.0) 
Anti-Anaerobic Antimicrobials*a 733 (55.5) 690 (50.2) 
Anti-Atypical Antimicrobialsb 793 (60.0) 762 (55.4) 
Anti-MRSA Antimicrobialsc 402 (30.4) 406 (29.5) 
Anti-Pseudomonal Antimicrobials*d 636 (48.1) 569 (41.4) 
Anti-Influenza Antimicrobials*e 7 (0.5) 68 (4.9) 
Intravenous Route Antimicrobials 924 (69.9) 905 (65.8) 
Digestive Route Antimicrobialsf 937 (70.9) 1005 (73.1) 
Length of Stay (days)* 5.0 (3.0-8.0) 4.0 (2.0-7.0) 
Days of Therapy* 5.0 (2.0-9.0) 4.0 (2.0-8.0) 
Any Surgery During the Antibiotic-Related 
admission 
189 (14.3) 163 (11.9) 
Laboratory Results during the antibiotic-
related Admission 
  
Maximum temperature (○F) 98.4 (98.0 -99.2) 98.4 (98.0 -99.1) 
Maximum WBC Count (cells 103/mm3) 9.5 (7.2 – 12.7) 9.5 (7.2 – 12.8) 
Previous Antibiotics, 90 days 417 (31.6) 462 (33.6) 
Previous Antibiotics, 365 days* 655 (49.6) 729 (53.0) 
Previous Hospitalization, 90 days* 609 (46.1) 720 (52.4) 
Previous Hospitalization, 365 days* 891 (67.4) 983 (71.5) 
Previous Any Surgery, 90 days 120 (9.1) 147 (10.7) 
Previous Pneumococcal Vaccine, 5 years* 222 (16.8) 593 (43.1) 
Previous Influenza Vaccine, 1 year* 874 (66.2) 980 (71.3) 
Data are mean ± standard deviation, median (interquartile range), or number (%) of patients.   4 
Differences assessed by Fisher’s exact or χ2 test (categorical data), t-test or Wilcoxon Rank Sum 5 
test (continuous data) as appropriate. 6 
 7 
MRSA=methicillin-resistant Staphylococcus aureus; WBC= White Blood Cell. 8 
 9 
*= p<0.05 10 
 11 
 26 
a= Antimicrobials with activity against anaerobes, included tigecycline, β-lactams/ β-lactamase 1 
inhibitors, cefoxitin, cefotetan, carbapenems, clindamycin, moxifloxacin, and metronidazole. 2 
b= Antimicrobials with activity against atypical pneumonia pathogens, included tetracyclines, 3 
tigecycline, macrolides, and fluoroquinolones. 4 
c= Antimicrobials with activity against MRSA, included tigecycline, daptomycin, telavancin, 5 
vancomycin IV, quinupristin/dalfopristin, linezolid, and ceftaroline. 6 
d= Antimicrobials with activity against Pseudomonas aeruginosa, included ticarcillin/clavulanate, 7 
piperacillin/tazobactam, ceftazidime, cefepime, imipenem, meropenem, doripenem, amikacin, 8 
gentamicin, tobramycin, ciprofloxacin, levofloxacin, polymyxin B, colistin, and fosfomycin. 9 
e= Antimicrobials with activity against Influenza, included oseltamivir. 10 
f= Digestive route included oral and rectal antimicrobials. 11 
 12 
 13 
 14 
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Table 3. Outcomes: Post-Antimicrobial Stewardship Period Compared with Pre- 1 
Antimicrobial Stewardship Period. 2 
Outcome 
No. of events/ No. of 
patients  Post-ASP 
No. of events/ No. of 
patients  Pre-ASP 
HR (95% CI) 
All-cause 7-Day 
Mortality 
   
Unadjusted 
33/1,375 25/1,321 1.269 (0.755-2.134) 
Adjusted 
33/1,375 25/1,321 1.165 (0.614-2.211) 
Matched 
13/553 11/553 1.182 (0.529-2.638) 
All-cause 14-
Day Mortality 
   
Unadjusted 72/1,375 52/1,321 1.337 (0.936-1.910) 
Adjusted 72/1,375 52/1,321 1.412 (0.915-2.179) 
Matched 31/553 21/553 1.429 (0.818-2.495) 
All-cause 30-
Day Mortality 
   
Unadjusted 118/1,375 92/1,321 1.243 (0.946-1.632) 
Adjusted 118/1,375 92/1,321 1.408 (1.011-1.960) 
Matched 53/553 38/553 1.378 (0.903-2.105) 
All-cause 
Inpatient 
Mortality 
   
Unadjusted 22/1,375 35/1,321 0.721 (0.422-1.229) 
Adjusted 22/1,375 35/1,321 0.600 (0.301-1.194) 
Matched 7/553 14/553 0.667 (0.188-2.362) 
Discharge    
Unadjusted 1,353/1,375 1,286/1,321 1.178 (1.091-1.272) 
Adjusted 1,353/1,375 1,286/1,321 1.031 (0.939-1.133) 
Matched 546/553 539/553 1.148 (0.979-1.346) 
30-Day 
Readmission 
   
Unadjusted 448/1,375 361/1,321 1.235 (1.075-1.419) 
Adjusted 448/1,375 361/1,321 1.150 (0.971-1.363) 
Matched 164/553 158/553 1.093 (0.869-1.376) 
CI=confidence interval; HR=hazard ratio; Pre-= Pre-Antimicrobial Stewardship Period; Post-= 3 
Post-Antimicrobial Stewardship Period. 4 
 5 
Adjusted by propensity score quintiles (reference quintile I). 6 
Propensity score matched within 0.001 caliper. 7 
 8 
The propensity was derived from an unconditional logistic regression model controlling for (C-9 
statistic 0.84) antimicrobials in the previous 90 days, hospitalization in the previous 90 days, age, 10 
current complication of surgery or medical care, antimicrobials in the previous 30 days, 11 
antimicrobials in the previous 365 days, current piperacillin/tazobactam exposure, body mass 12 
index category, current adverse drug event, current alcohol abuse, current arrhythmia, current 13 
cancer, current cerebrovascular disorder, current coronary heart disease, current congestive 14 
heart failure, current coagulopathy, current chronic renal disease, current chronic respiratory 15 
disease, current tobacco use, current deficiency anemia, current human immunodeficiency virus, 16 
 28 
current history of tobacco use, current cellulitis or abscess, current bacteremia, current influenza 1 
infection, current methicillin-resistant Staphylococcus aureus infection, current skin/subcutaneous 2 
infection, current urinary tract infection, current pulmonary circulation disorder, current positive 3 
coagulase-negative Staphylococcus culture, current positive Escherichia coli culture, current 4 
positive Pseudomonas aeruginosa culture, current positive Streptococcus species culture, current 5 
rheumatoid arthritis, current valvular disease, current Elixhauser score, creatinine, days of 6 
antimicrobial therapy, ethnicity, current beta-lactam/ beta-lactamase inhibitor exposure, current 7 
anti-influenza drug exposure, current fluoroquinolone exposure, current macrolide exposure, 8 
current metronidazole exposure, current tetracycline class exposure, current digestive route 9 
antimicrobial exposure, current anti-atypical drug exposure, current anti-Clostridium difficile drug 10 
exposure, current other antimicrobial exposure, gender, previous alcohol abuse, previous burn, 11 
pervious coronary heart disease, previous chronic ulcer, previous coagulopathy, previous chronic 12 
renal disease, previous tobacco use, previous deficiency anemia, previous diabetes mellitus, 13 
previous drug abuse, previous endocarditis, previous human immunodeficiency virus, previous 14 
hypertension, previous history of tobacco use, previous cellulitis or abscess, previous bacteremia, 15 
previous Gram negative infection, previous influenza infection, previous pneumonia, previous 16 
Pseudomonas species infection, previous Staphylococcus aureus infection, previous surgical site 17 
infection, previous Streptococcus species infection, previous urinary tract infection, previous 18 
severe liver disease, previous obesity, previous other neurologic disorder, previous osteomyelitis, 19 
previous positive blood culture, previous positive catheter tip culture, previous positive other site 20 
culture, previous positive skin culture, previous positive Proteus species culture, previous positive 21 
Streptococcus culture, previous positive Enterococcus faecalis culture, previous complication of 22 
surgery or medical care, previous valvular disease, hemoglobin, previous Charlson Score, 23 
previous Elixhauser score, hospitalization in the previous 180 days, hospitalization in the previous 24 
30 days, marital status, pneumococcal vaccination in the previous 10 years, pneumococcal 25 
vaccination in the previous 1 year, previous skin/ subcutaneous infection, previous urinary tract 26 
infection, race, and treating specialty. 27 
28 
 29 
Table 4. Mean Monthly Antimicrobial Use in Days of Therapy per 1000 Patient Days 1 
(DOT/1000PD) by Period. 2 
 3 
Antimicrobial 
Category 
Pre-Antimicrobial 
Stewardship 
Period (DOT/1000 
PD) 
Post-Antimicrobial 
Stewardship 
Period 
(DOT/1000 PD) 
Percent Change in 
Antimicrobial Use 
(%) 
Overall  494.7 ± 54.1 494.9 ± 70.4 0.0 
Intravenous Route 312.3 ± 38.9 298.0 ± 48.4 -4.6 
Digestive Routea 185.3 ± 26.1 200.6 ± 37.2 +8.3 
Broad-Spectrum*b 231.9 ± 29.3 205.6 ± 29.0 -11.3 
Fluoroquinolone* 71.0 ± 8.6 51.8 ± 11.1 -27.0 
3rd-4th Generation CS 40.9 ± 12.8 37.6 ± 7.4 -8.1 
Carbapenems 11.3 ± 7.7 8.7 ± 4.3 -23.0 
Vancomycin 73.3 ± 12.8 75.8 ± 20.3 +3.4 
Piperacillin/Tazobactam 88.1 ± 10.9 83.7 ± 18.9 -5.0 
Anti-MRSAc 83.9 ± 15.2 82.7 ± 25.0 -1.4 
Anti-Pseudomonal*d 152.1 ± 18.8 128.3 ± 22.1 -15.6 
Anti-ESBLe 12.3 ± 7.3 8.2 ± 4.3 -33.3 
Anti-Anaerobicd 186.1 ± 26.9 168.7 ± 28.5 -9.3 
Anti-CDIg 46.9 ± 18.9 44.5 ± 16.2 -5.1 
Anti-Atypicalh 114.0 ± 25.5 105.7 ± 18.3 -7.3 
Data are mean ± standard deviation or % change.  The DOT represents the sum of the days for 4 
which a single antimicrobial was administered, regardless of the number of doses administered 5 
or dosage strength 6 
 7 
CS= cephalosporins; CDI= Clostridium difficile infection; ESBL= extended spectrum β-lactamase, 8 
IV=intravenous; MRSA=methicillin-resistant Staphylococcus aureus; PO=oral; PR=rectal 9 
 10 
*= p<0.0 11 
 12 
a= Digestive route use included oral and rectal antimicrobials. 13 
b= Broad-spectrum antimicrobial use included β-lactams/ β-lactamase inhibitors, 3rd and 4th 14 
generation cephalosporins, carbapenems, and fluoroquinolones. 15 
c= Antimicrobials with activity against MRSA, included tigecycline, daptomycin, telavancin, 16 
vancomycin IV, quinupristin/dalfopristin, linezolid, and ceftaroline. 17 
d= Antimicrobials with activity against Pseudomonas aeruginosa, included ticarcillin/clavulanate, 18 
piperacillin/tazobactam, ceftazidime, cefepime, imipenem, meropenem, doripenem, amikacin, 19 
gentamicin, tobramycin, ciprofloxacin, levofloxacin, polymyxin B, colistin, and fosfomycin. 20 
e= Antimicrobials with activity against ESBLs, included tigecycline, carbapenems, polymyxin B, 21 
colistin, and fosfomycin. 22 
f= Antimicrobials with activity against anaerobes, included tigecycline, β-lactams/ β-lactamase 23 
inhibitors, cefoxitin, cefotetan, carbapenems, clindamycin, moxifloxacin, and metronidazole. 24 
g= Antimicrobials with activity against Clostridium difficile, included vancomycin PO/PR, 25 
fidaxomicin, and metronidazole PO. 26 
h= Antimicrobials with activity against atypical pneumonia pathogens, included tetracyclines, 27 
tigecycline, macrolides, and fluoroquinolones. 28 
 29 
 30 
 31 
  32 
 30 
Table 5. Significant Changes in Antimicrobial Use using Interrupted Time Series Analysis. 1 
 2 
Antimicrobial 
Category 
DOT/1000PD per 
month 
95% Confidence 
Interval 
P-value 
Change in level 
Digestive Routea +110.1 15.2 - 205.0 0.025 
Anti-Anaerobicb +110.6 43.2 - 177.1 0.003 
Anti-CDIc +76.1 32.0- 120.1, 0.002 
Change in trend 
Carbapenems +1.5 0.1-3.0 0.035 
Models for change in level contained only the baseline trend and level change. 3 
Models for change in trend contained the baseline trend, level change, and intervention trend. 4 
 5 
CDI= Clostridium difficile infection; DOT/1000PD= Days of therapy per 1000 patient days; 6 
PO=oral; PR=rectal 7 
 8 
 9 
a= Digestive route use included oral and rectal antimicrobials. 10 
b= Antimicrobials with activity against anaerobes, included tigecycline, β-lactams/ β-lactamase 11 
inhibitors, cefoxitin, cefotetan, carbapenems, clindamycin, moxifloxacin, and metronidazole. 12 
c= Antimicrobials with activity against Clostridium difficile, included vancomycin PO/PR, 13 
fidaxomicin, and metronidazole PO. 14 
 15 
 16 
  17 
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Table 6.  Antimicrobial Resistance in Pre- and Post-Antimicrobial Stewardship Periods. 1 
Organism Antimicrobial Tested Pre-
Antimicrobial 
Stewardship 
Period, Percent 
Resistance (n 
isolates tested)  
Post-
Antimicrobial 
Stewardship 
Period, Percent 
Resistance (n 
isolates tested) 
Gram-Positive Organisms  
Enterococcus 
faecalis Ampicillin 0 (114) 0 (124) 
 
Gentamicin 28.4 (102) 26.6 (124) 
 
Vancomycin 6.4 (109) 3.2 (125) 
Enterococcus 
faecium Ampicillin 
90.0 (20) 77.8 (18) 
 Gentamicin 0 (16) 5.3 (19) 
 Tetracycline 100 (13) 90.9 (11) 
 Vancomycin 89.5 (19) 61.1 (18) 
MRSA 
Clindamycin 
43.0 (121) 
 
44.1 (143) 
 Gentamicin 0.7 (146) 0 (162) 
 Tetracycline 2.7 (146) 3.7 (162) 
 Trimethoprim-sulfamethoxazole 0 (146) 1.2 (162) 
 Vancomycin 0.7 (146) 0 (161) 
MSSA 
Clindamycin 
20.0 (168) 27.0 (163) 
 Erythromycin 32.7 (168) 36.2 (163) 
 Gentamicin 2.1 (190) 1.1 (179) 
 Penicillin 81.1 (190) 77.1 (179) 
 Tetracycline 3.2 (190) 2.2 (179) 
 Trimethoprim-sulfamethoxazole 2.1 (190) 1.1 (179) 
 Vancomycin 0 (190) 1.1 (179) 
Gram-negative Organisms  
Klebsiella 
pneumoniae Amikacin 
2.3 (128) 4.0 (124) 
 Ampicillin 96.9 (128) 100 (124) 
 Ampicillin-sulbactam 20.3 (128) 26.6 (124) 
 Aztreonam 9.4 (128) 13.7 (124) 
 Cefazolin* 11.7 (128) 23.4 (124) 
 Cefepime* 4.7 (128)  12.1 (124) 
 Ceftriaxone* 6.3 (128) 13.7 (124) 
 Ciprofloxacin* 10.3 (126) 20.7 (121) 
 Gentamicin* 6.3 (128) 15.3 (124) 
 Imipenem 0 (127) 0 (122) 
 Piperacillin-tazobactam* 0 (117) 5.6 (107) 
 Trimethoprim-
sulfamethoxazole* 
9.4 (128) 21.0 (124) 
Acinetobacter 
baumannii Amikacin 
12.5 (8) 9.1 (11) 
 32 
 Cefepime 25.0 (8) 18.2 (11) 
 Ceftazidime 37.5 (8) 9.1 (11) 
 Ciprofloxacin 12.5 (8) 9.1 (11) 
 Gentamicin 12.5 (8) 18.2 (11) 
 Imipenem 14.3 (7) 20.0 (10) 
 Trimethoprim-sulfamethoxazole 12.5 (8) 18.2 (11) 
Pseudomonas 
aeruginosa Amikacin 
13.1 (130) 12.4 (121)  
 Aztreonam 26.9 (130) 31.4 (121) 
 Cefepime 7.6 (131) 10.7 (122) 
 Ceftazidime 12.2 (131) 10.0 (120) 
 Ciprofloxacin 22.7 (132) 20.7 (121) 
 Gentamicin 19.7 (132) 23.8 (122) 
 Imipenem 11.4 (132) 10.7 (122) 
 Piperacillin-tazobactam 3.9 (128) 4.4 (114) 
 Tobramycin 0.8 (131) 5.8 (121) 
Escherichia coli Amikacin 0 (243) 1.0 (256) 
 Ampicillin 44.0 (243) 42.0 (257) 
 Ampicillin-sulbactam 39.9 (243) 35.9 (256) 
 Aztreonam 6.2 (243) 5.1 (257) 
 Cefazolin 14.0 (243) 14.0 (256) 
 Cefepime 4.1 (243) 3.9 (257) 
 Ceftriaxone 4.9 (243) 5.1 (256) 
 
Ciprofloxacin 
25.9 (243) 
 
20.1 (254) 
 Gentamicin 22.0 (243) 18.0 (257) 
 Imipenem 0 (243) 0 (257) 
 Piperacillin-tazobactam 2.1 (234) 2.1 (243) 
 Trimethoprim-sulfamethoxazole 23.0 (243) 18.0 (255) 
 1 
MRSA=methicillin-resistant Staphylococcus aureus; MSSA= methicillin-sensitive Staphylococcus 2 
aureus 3 
 4 
*= p<0.05 5 
 6 
 33 
Fig. 1. Antimicrobial Stewardship Patient Workup Template. 
 
 
Fig. 2. Antimicrobial Stewardship Interventions and Acceptance Rates. 
Data expressed as number of interventions (% accepted). 
 
IV= Intravenous; PO=Oral; NA= Intervention no longer appliable, for example patient discharged 
home, or antibiotic of interest was switched or discontinued. 
 
*=Antimicrobial optimization includes any recommendation to improve the drug, dose, or duration 
of an antimicrobial. 
 
 
Fig. 3. Antimicrobial Use Comparison Pre- and Post- Antimicrobial Stewardship Program 
(ASP) Implementation. 
 
CS= cephalosporins; CDI= Clostridium difficile infection; ESBL= extended spectrum β-lactamase, 
MRSA=methicillin-resistant Staphylococcus aureus 
 
*= p<0.05 
